SCHEMBL277377

SCHEMBL277377

CCCOCC(O)COc1ccc(-c2nc(-c3ccc(OC)cc3)nc(-c3ccc(OCC(O)COCCC)cc3O)n2)c(O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
LMNA P02545 3/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
GPR35 Q9HC97 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
NPC1 O15118 2/20 0.42
HTT P42858 3/20 0.42
ADRB3 P13945 2/20 0.41
CASR P41180 1/20 0.40
MAPK1 P28482 3/20 0.39
ADRB2 P07550 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ADRB1 P08588 1/20 0.39
KDM4E B2RXH2 1/20 0.39
NOD2 Q9HC29 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
MAPK10 P53779 1/20 0.39
PTK2B Q14289 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7887570 0.96 MAPT (0.43) MAPTLMNACNR1CNR2GPR35
SCHEMBL15127483 0.96 CASR (0.42) MAPTLMNACNR1CNR2GPR35
SCHEMBL12755384 0.93 CASR (0.40) MAPTLMNACNR1CNR2GPR35
SCHEMBL3833778 0.93 LMNA (0.42) MAPTLMNACNR1CNR2GPR35
SCHEMBL21514817 0.91 PLA2G4B (0.43) MAPTLMNACNR1CNR2GPR35
SCHEMBL21514725 0.91 NPC1 (0.46) MAPTLMNACNR1CNR2GPR35
SCHEMBL8216433 0.90 LMNA (0.42) MAPTLMNACNR1CNR2GPR55
SCHEMBL9567378 0.87 PLA2G4B (0.39) MAPTLMNACNR1CNR2GPR35
SCHEMBL14998017 0.87 CASR (0.38) MAPTLMNACNR1CNR2GPR35
SCHEMBL6334661 0.86 PLA2G4B (0.41) MAPTLMNACNR1CNR2GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2945601-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND A LIPOPHILIC BENZOTRIAZOLE UV-SCREENING AGENT AND/OR A BIS-RESORCINYL TRIAZINE COMPOUND OREAL (FR) 2018-08-22 EP claimed
US-9949475-B2 Composition comprising active ingredient, oil and ionic liquid BASF SE (DE) 2018-04-24 US claimed
EP-2959885-A1 STABLE COSMETIC AND DERMATOLOGICAL PREPARATION WITH HIGH SUN BLOCK FACTOR Beiersdorf AG (DE) 2015-12-30 EP claimed
EP-2945601-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND A LIPOPHILIC BENZOTRIAZOLE UV-SCREENING AGENT AND/OR A BIS-RESORCINYL TRIAZINE COMPOUND L'Oréal (FR) 2015-11-25 EP claimed
US-8999299-B2 Photoprotective cosmetic compositions comprising silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups and non-silicon-containing lipophilic triazine compound UV-screening agents L'OREAL (FR) 2015-04-07 US claimed
WO-2014111563-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND A LIPOPHILIC BENZOTRIAZOLE UV-SCREENING AGENT AND/OR A BIS-RESORCINYL TRIAZINE COMPOUND L'OREAL (FR) 2014-07-24 WO claimed
EP-2025324-B1 Method of Quenching Electronic Excitation of Chromophore-Containing Organic Molecules in Photoactive Compositions HALLSTAR INNOVATIONS CORP (US) 2013-08-14 EP claimed
US-20120230931-A1 Sun-Care Compositions ISP INVESTMENTS LLC 2012-09-13 US claimed
EP-1216690-B1 Cosmetic and dermatological sunscreen compositions containing asymmetrically substituted triazine derivatives and citric esters surfactants BEIERSDORF AG (DE) 2012-07-25 EP claimed
US-8173729-B2 Photosensitive resin composition DONGJIN SEMICHEM CO., LTD. (KR) 2012-05-08 US claimed
EP-1013263-A2 Cosmetic and dermatologic W/O-emulsion containing boron nitride Beiersdorf Aktiengesellschaft (DE) 2000-06-28 EP claimed
EP-1013262-A2 Cosmetic and dermatologic o/w-emulsions containing boron nitride Beiersdorf Aktiengesellschaft (DE) 2000-06-28 EP claimed
EP-1000611-A1 Use of triglyceridic waxes to enhance the sun protecting factor of a sunscreen Beiersdorf Aktiengesellschaft (DE) 2000-05-17 EP claimed
EP-0998910-A1 Cosmetic and dermatologic aqueous dispersions containing triglyceridic waxes Beiersdorf Aktiengesellschaft (DE) 2000-05-10 EP claimed
EP-0976391-A1 Cosmetic and dermatological W/O emulsions, containing ionic and/or amphoteric detergents and the presence of an amount of silicone-emulgators Beiersdorf Aktiengesellschaft (DE) 2000-02-02 EP claimed
EP-0970688-A2 Use of iron, titanium mixed oxides for increasing the sun protection factor of cosmetic or dermatological sunscreens Beiersdorf Aktiengesellschaft (DE) 2000-01-12 EP claimed
EP-0963753-A2 Utilisation of C20-40 dialkyldimerate for increasing the light protection factor and/or the UV-A protection of cosmetic or dermatologic light protection agents Beiersdorf Aktiengesellschaft (DE) 1999-12-15 EP claimed
EP-0922447-A2 Utilisation of C18-38 alkylhydroxystearoylsterates for increasing the light protection factor and/or the UV-A protection of cosmetic or dermatologic light protection agents Beiersdorf Aktiengesellschaft (DE) 1999-06-16 EP claimed
EP-0904770-A1 Utilisation of X-ray-amorphous oxids for increasing the light protectionfactor and/or the UV-protection of cosmetic or dermatologie light protection agents Beiersdorf Aktiengesellschaft (DE) 1999-03-31 EP claimed
EP-0897715-A2 Cosmetic and dermatological light protecting agents containing U.V. filtering substances as solid particles and polymeric U.V. filtering substances on silicone basis Beiersdorf Aktiengesellschaft (DE) 1999-02-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120230931-A1 Sun-Care Compositions CCNY, WIZ, SUN2 MAPT 1161/4885LMNA 1117/4885CNR1 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.